In line with the NICE process we would have published the Final Appraisal Determination for this topic today. However, NHS England has made representations to NICE expressing serious concerns with the operation of the complex patient access scheme in place for the already recommended indication for lenalidomide in NICE technology appraisal 171, and the revised one proposed for the current appraisal.
NICE’s guidance executive concluded that the concerns about the patient access scheme are sufficient to warrant suspension of the current appraisal.
NICE has asked the company to work with NHS England and the NICE Patient Access Scheme Liaison Unit to urgently seek a solution that allows patient access to lenalidomide for this indication. The timelines for this are outside of NICEs control, but as soon timelines become clearer, this appraisal will restart.